ELI LILLY & Co is 18.9x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($1.072 T vs $56.80 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | REGN | LLY |
|---|---|---|
| Market cap | $56.80 B | $1.072 T |
| US-listed rank | #292 | #10 |
| Revenue (latest FY) | $14.34B | $65.18B |
| Net income (latest FY) | $4.50B | $20.64B |
| Net margin | 31.4% | 31.7% |
| P/E (trailing FY) | 12.6 | 51.9 |
| SEC filings | 985 | 989 |
ELI LILLY & Co is 18.9x more valuable than REGENERON PHARMACEUTICALS, INC. by market capitalization ($1.072 T vs $56.80 B).
In their latest fiscal years, REGENERON PHARMACEUTICALS, INC. reported $14.34B in revenue while ELI LILLY & Co reported $65.18B.
Full pages: REGENERON PHARMACEUTICALS, INC. and ELI LILLY & Co, or browse the full rankings.